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Magnetic resonance imaging (MRI) is the mainstay method for the radiological imaging of the small bowel in patients with
inflammatory bowel disease without the use of ionizing radiation. There are circumstances where imaging using ionizing
radiation is required, particularly in the acute setting. This usually takes the form of computed tomography (CT). There has
been a significant increase in the utilization of computed tomography (CT) for patients with Crohn’s disease as patients are
frequently diagnosed at a relatively young age and require repeated imaging. Between seven and eleven percent of patients with
IBD are exposed to high cumulative effective radiation doses (CEDs) (>35–75mSv), mostly patients with Crohn’s disease
(Newnham E 2007, Levi Z 2009, Hou JK 2014, Estay C 2015). This is primarily due to the more widespread and repeated use of
CT, which accounts for 77% of radiation dose exposure amongst patients with Crohn’s disease (Desmond et al., 2008). Reports
of the projected cancer risks from the increasing CT use (Berrington et al., 2007) have led to increased patient awareness
regarding the potential health risks from ionizing radiation (Coakley et al., 2011). Our responsibilities as physicians caring for
these patients include education regarding radiation risk and, when an investigation that utilizes ionizing radiation is required,
to keep radiation doses as low as reasonably achievable: the “ALARA” principle. Recent advances in CT technology have
facilitated substantial radiation dose reductions in many clinical settings, and several studies have demonstrated significantly
decreased radiation doses in Crohn’s disease patients while maintaining diagnostic image quality. However, there is a balance to
be struck between reducing radiation exposure and maintaining satisfactory image quality; if radiation dose is reduced
excessively, the resulting CT images can be of poor quality and may be nondiagnostic. In this paper, we summarize the available
evidence related to imaging of Crohn’s disease, radiation exposure, and risk, and we report recent advances in low-dose CT
technology that have particular relevance.
1. Introduction
Crohn’s disease is characterized by transmural inflammation
that may affect any part of the gastrointestinal tract, and it is a
life-long condition that relapses and remits throughout its
course [1]. Improved understanding of the pathogenesis
of Crohn’s disease combined with recent availability of
immunomodulatory treatments has expanded the range
of medical therapies available to physicians who treat
patients with Crohn’s disease [2]. Tailored imaging inves-
tigations are a key component of the decision-making pro-
cess for a number of reasons. First, determining the extent
and activity of Crohn’s disease informs treatment-related
decisions. This requires radiological evaluation of small intes-
tine and extra intestinal manifestations as well as endoscopic
(gastroscopy and colonoscopy) and laboratory investigations
[3]. Second, monitoring disease progression and response to
treatment including surgery using imaging allows therapeutic
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optimization. Appropriate investigations allow early detec-
tion of complications, which potentially require surgical
treatment including fibrostenotic disease, which can cause
bowel obstruction, or fistulating disease which can lead to
abscess formation ([4]). Third, treatment side effects range
from nausea, which may limit compliance, to an increased
risk of lymphoproliferative disorders, lymphoma, melanoma,
and nonmelanoma skin cancers associated with immunosup-
pressant [5–7]. Similarly, chronic inflammation of the gastro-
intestinal tract increases the risk of colorectal cancer [5–7].
These associations sometimes necessitate surveillance strate-
gies for patients with Crohn’s disease [4].
2. Nonionising Radiation Modalities
The use of imaging modalities that do not require ionizing
radiation is the preferred method of reducing radiation
exposure among patients with Crohn’s disease. These
include magnetic resonance imaging (MRI), ultrasound, and
capsule endoscopy.
2.1. MRI. MRI is used to a great effect to identify both acute
and chronic features of Crohn’s disease [8]. Magnetic reso-
nance enterography (MRE) is the preferred method of small
bowel cross-sectional imaging. This is partly due to concern
regarding cumulative ionizing radiation exposure from CT
and fluoroscopy, especially in children and young adults,
who will undergo many examinations throughout their life,
otherwise amassing a potentially significant cumulative radi-
ation exposure [9]. MRI is well suited for evaluating small-
bowel inflammatory disease with reported sensitivity of
93% and specificity of 93% [10]. MRI offers superior soft
tissue contrast resolution, multiplanar capability, and the
potential of obtaining functional information. The main
indications for MRE include small bowel imaging in
patients with suspected or surveillance of known Crohn’s
disease. The examination may also be combined with the
assessment of perianal disease, which is also optimally per-
formed using MRI.
The absence of ionizing radiation is a strong advantage of
MR imaging. These advantages often outweigh the disadvan-
tage of the relatively long time it takes to perform MR enter-
ography and increased cost relative to CT [11, 12]. In the
clinical setting of a critically ill patient, the MRI suite presents
many additional challenges over CT in terms of patient
safety, especially regarding monitoring lines and support
equipment which need to be nonferromagnetic. MRI
imaging in the setting of Crohn’s disease also often requires
the administration of a gadolinium-based contrast agent
(GBCA), which has recently come under increasing scrutiny
due to gadolinium deposition in the dentate nuclei, pons, glo-
bus pallidus, and thalamus of patients undergoing multiple
MRIs requiring GBCA administration [13, 14]. The clinical
significance of this deposition is as yet unknown but has led
to the European Medicine Agency’s Pharmacovigilance Risk
Assessment Committee recently recommending the suspen-
sion of marketing authorization for four linear GBCAs [15].
2.2. Diffusion-Weighted Imaging. Diffusion-weighted imag-
ing (DWI) can be used as a valuable sequence for the depic-
tion of lesions and can change the MRI protocol and obviate
the need for gadolinium administration. While long used in
other parts of the body such as the brain, the use of DWI to
assess bowel is relatively new. Increased T2 signal intensity
and restricted diffusion on DWI of the bowel wall have been
shown to relate to acute inflammation [16].
The ability of DWI to differentiate between actively
inflamed small bowel segments and normal small bowel in
CD has been demonstrated, showing superior sensitivity ver-
sus dynamic contrast-enhanced MR [17]. A prospective
study involving 31 patients with CD compared DWI with
conventional MRE in estimating small bowel inflammation.
DWI hyperintensity was highly correlated with disease activ-
ity evaluated using conventional MRE [18]. DWI has also
been shown to complement T2-weighted imaging of the
internal fistula and sinus tracts [19].
However, improved spatial resolution to facilitate thinner
image slices is required before DWI can replace gadolinium-
enhanced sequences or be used as a reliable quantitative bio-
marker for monitoring disease activity [20].
Recent developments in MRI technology, such as faster
gradient sequences and refined receiver coils, will boost its
convenience and allow for more efficient MR imaging. Not
only should these advances increase patient through-put
but these will also reduce motion artifact and improve image
spatial resolution which are current limitations of MRI com-
pared with CT. Being radiation-free, these advances are most
significant for younger cohorts of patients with CD and those
undergoing serial and repeated imaging studies for known
CD [21].
2.3. Ultrasound. The pathognomonic finding of Crohn’s dis-
ease is discontinuous and dishomogeneous transmural
inflammation extending through all layers of the intestinal
wall. The presence of these features forms the basis of ultra-
sound (US) diagnosis of Crohn’s disease. Standard B-mode
ultrasound is of limited utility in this setting, but some recent
papers have suggested that contrast-enhanced US may be of
use in determining disease activity [22–24], although this is
slow to be implemented into widespread clinical practice.
US assessment in patients with CD typically reveals stiff
and thickened bowel walls variably associated with an alter-
ation of normal peristaltic activity in the small bowel as well
as the absence of colonic haustral folds. Contrast-enhanced,
power, and color Doppler ultrasound allow for increased
accuracy in the assessment of the small bowel CD [25].
Recent studies have shown that US reliably locates and char-
acterizes inflammatory infiltration of the bowel wall and
assesses local abnormalities such as abscess formation [26].
A significant problem with the use of ultrasound in this set-
ting, however, is that it is heavily operator-dependent and is
extremely time-consuming.
2.4. Capsule Endoscopy. Capsule endoscopy (CE), introduced
in 2000 [27], is an increasingly available method for assessing
small intestinal pathology. Current indications for CE
include the identification of obscure gastrointestinal tract
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bleeding (OGIB) and investigation of Crohn’s disease, small
intestine tumours, and malabsorptive states [28]. In the eval-
uation of Crohn’s disease, stricturing or penetrating disease
increases the risk of capsule retention (defined as the capsule
remaining in the gastrointestinal tract for longer than 2
weeks [28]) and capsule perforation [29, 30]. CT and MRI
techniques to determine luminal patency are useful prior to
CE. Importantly, MRI use is contraindicated in cases of cap-
sule retention [28], which may occur due to gastroparesis and
motility disorders, as well as for mechanical reasons second-
ary to complications of Crohn’s disease [28, 30]. Further-
more, nonspecific mucosal abnormalities are often detected
with CE and, without biopsy capability, this can lead to high
false positive rates of Crohn’s disease [29], reducing benefits
of CE over radiological modalities. Capsule aspiration is a
rare complication, most often seen in patients with neurolog-
ical or swallowing disorders and reduced or absent cough
[29]. In carefully selected cases, particularly stable OGIB
and nonstricturing Crohn’s disease, CE is a safe, noninvasive
investigative tool that reduces radiation exposure for patients
in the evaluation of small intestinal mucosa.
3. Computed Tomography
3.1. Background. CT uses ionizing radiation in the form of
X-rays, to form an image of a patient. The traditional method
of image reconstruction (i.e., the reconstruction algorithm)
used by the computer to form the images is called filtered
back projection (FBP). This method relies on the patient
being exposed to a relatively large dose of radiation in order
to create diagnostic quality images. Image noise becomes an
issue at low radiation doses with FBP, and images with large
amounts of noise can significantly impair the ability of the
interpreting radiologist to form an accurate opinion of the
images. Recent advances in the computational power and
efficiency have facilitated the use of iterative reconstruction
of CT images. These new iterative reconstruction (IR) tech-
niques have some major advantages over FBP: they reduce
image noise, reduce the occurrence of artefacts (e.g. streak
from metallic implants), and facilitate the acquisition of CT
images at much lower radiation doses while maintaining
diagnostic image quality [31].
3.2. Radiation Dose. Three main metrics are used to estimate
patient radiation exposure in CT. The radiation dose output
from the scanner is represented by the CT dose index
(CTDI)vol measured in milligrays (mGy); the dose over the
total length of the scan is represented by the dose-length
product (DLP) measured in mGy·cm; the effective dose
(ED), measured in millisieverts (mSv), which represents the
equivalent whole-body dose that would have the same risk
of the biologic effect, can be derived by multiplying DLP by
a conversion factor based on the CT scan parameters and
the body part imaged [32]. A standard CT of the abdomen
and pelvis (CT-AP) exposes the patient to an ED of approx-
imately 8mSv although values reported in the literature
range from 3.5mSv to 25mSv [33]. The radiation exposure
associated with CT-AP is significantly more than the annual
natural background radiation of 3–4mSv received by the
average person from the environment [34].
3.3. Risks of Radiation Exposure. High-dose radiation expo-
sure leads to predictable deterministic effects that only occur
above a certain threshold dose, and the severity of the injury
once this threshold is reached is dose dependent; examples of
this include skin burns (threshold 2Gy) [35, 36] and cataract
formation (threshold 0.5Gy) [37]. However, even below
these thresholds, exposure to low-level ionizing radiation is
associated with stochastic effects; these are probabilistic
effects that are unrelated to dose and are responsible for can-
cer induction in human cells.
The current widely accepted model of cancer risk from
low-level radiation exposure is called the linear no-
threshold model, whereby any exposure to ionizing radia-
tion, however small, has the potential to cause harm. Several
clinical studies have attempted to quantify cancer risk from
CT radiation exposure [38, 39], but this is very difficult to
accurately perform as the increased risk due to diagnostic
imaging is small and it is extremely difficult to control for
confounding factors in the required large study population
over a long time period. Another difficulty in risk quantifica-
tion is that there is usually a latent time from radiation expo-
sure to cancer development of many years.
Age at the time of radiation exposure is known to be an
independent risk factor for subsequent cancer mortality
[40], and this is particularly relevant in the setting of Crohn’s
disease where most patients are diagnosed between the ages
of 15 and 40; one large US epidemiological study reported a
median age at the diagnosis of 29.5 years [41].
Patient knowledge of the risk associated with radiation
exposure is generally low [42], and the information available
to these patients, primarily from the internet, can be of ques-
tionable accuracy [43], so it is the responsibility of referring
physicians and radiologists to communicate these risks to
patients in an easily understandable and effective way. Guid-
ance on how to source accurate information on the internet
may be very helpful to patients, similar to the way in which
physicians appraise medical literature. This includes factors
such as the presence of Health on the Net Foundation Code
of Conduct Certification (HONcode), an identifiable author,
and references to the peer-reviewed literature [43].
Some published estimates of cancer risk include a 3-fold
increased risk of leukaemia with 50mGy exposure as a child
[38], a 3-fold risk of brain cancer with 60mGy exposure as a
child [38], the induction of 125 breast cancers per 100,000
women screened between ages 40 and 74 [44], and a 1.8%
increase in lung cancers if 50% of the population between
aged 50 and 75 were screened for lung cancer with CT
annually [45].
However, the issue of estimation of risk associated with
exposure to ionizing radiation in the diagnostic range
remains extremely controversial. With increased attention
to this subject in the media and more alarmingly on the inter-
net and in social media, physicians must ensure that misin-
formation does not lead to situations where clinically
indicated CT scans are being refused by patients because of
exaggerated fears of developing malignancy.
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Medical imaging now accounts for approximately 50% of
total population radiation dose [46], and CT accounts for
approximately 60% of the dose received from medical imag-
ing [47]. The importance of patient radiation exposure from
serial CT examinations has been highlighted by the Interna-
tional Commission on Radiological Protection (ICRP) in its
Publication 102 [48]. It is believed that any dose of radiation,
however small, has the potential to cause harm, and so the
increased radiation dose from CT is of concern to many
[40, 49]. For now and until there is irrefutable contrary evi-
dence, the “as low as reasonably achievable” (ALARA) prin-
ciple guides radiation protection practices [50, 51].
3.4. CT in Crohn’s Disease. CT imaging as an alternative of
MRI and ultrasound is often used for imaging in Crohn’s dis-
ease due to its availability, accessibility, familiarity, rapid
acquisition time, and ability to evaluate mural, extramural,
and extraintestinal manifestations in a single examination
[3]. There are clinical circumstances where CT is the pre-
ferred method of imaging assessment, for example, in the
acute setting, postoperatively, in patients with contraindica-
tions to MRI, or in claustrophobic patients. The development
of low-dose CT scans can reduce patient radiation exposure
which is particularly important when required for young
patients with CD. It is of particular use in acutely unwell
patients for the assessment of abscess formation or perfora-
tion [52]. CT enterography (CTE) is a variation of routine
CT that specifically assesses the extent and severity of CD
in the small bowel. It is performed with the combination of
1 litre of a neutral or low-density oral drink/beverage with
intravenous iodinated contrast media. This combination
optimizes luminal distention and contrast resolution in the
small bowel and improves visualization of mural abnormali-
ties such as strictures or fistulae. Diagnostic criteria for
Crohn’s disease using CTE include bowel wall thickening,
bowel hyperemia, submucosal fat deposition, and lymphade-
nopathy. This cross-sectional imaging technique can also
detect complications of CD including bowel obstruction,
fistula, perforation, or abscess [53].
CTE is indicated in symptomatic patients, older patients
(over 35 years old), and when there are contraindications to
MR imaging [54]. Conventional CT is preferred for acutely
unwell patients especially where there are signs of abscess
formation or hollow viscus perforation.
Low-dose CTE using iterative reconstruction techniques
(e.g., model-based iterative reconstruction, adaptive statisti-
cal iterative reconstruction, and sinogram-affirmed iterative
reconstruction) has been found to be sensitive and specific
for the detection of active inflammatory changes of CD while
utilizing radiation doses significantly lower than those associ-
ated with conventional techniques. [55] There are known risk
factors in Crohn’s disease patients that tend to result in
higher lifetime cumulative effective doses, including a history
of surgery, biologic therapy, pain-predominant symptoms,
isolated ileal disease, and structuring or penetrating Crohn’s
disease [56–58]. Between 7 and 11% of patients with IBD
are exposed to high CED (>35–75mSv), mostly patients with
CD [59–62].
3.5. Low-Dose CT. While there is no standard definition for
what constitutes a low-dose abdominal CT protocol, we con-
sider scans where the effective dose delivered approaches that
of a standard abdominal plain film or KUB radiograph to be a
low-dose CT examination. There have been huge strides
made recently in the attempts to reduce the radiation expo-
sure to patients from CT. Dose reduction techniques include
automatic tube current modulation [63], truncated protocols
with fewer images [64], increasing acceptable image noise
[65], reduced mA and kV scanning, and clinical use of new
iterative reconstruction techniques [66, 67]. There is a fine
balance to be struck between reducing individual patient
radiation exposure and maintaining sufficient image quality
to allow an accurate diagnosis to be made, and this is an area
of intensive research.
An example of parameters for a low-dose abdominal CT
protocol at our institution is shown in Table 1. The low-dose
protocol is designed to impart a radiation exposure of
10–20% of a routine abdominal CT. The data are recon-
structed using a pure iterative reconstruction algorithm
(model-based iterative reconstruction, MBIR, Veo, GE
Healthcare, GEMedical Systems, Milwaukee, WI). The mean
effective radiation dose imparted by such a protocol is
0.83mSv for normal weight patients increasing to 2.0 for
overweight patients [67]. The typical conventional protocol
effective radiation dose is 6.1mSv. Both low-dose CT of the
abdomen and pelvis and CTE can be performed using these
parameters and appropriate patient preparation. It is impor-
tant to highlight that imaging parameters need to be tailored
towards the technology being used, the patient size, and the
familiarity of the reporting radiologist with the altered
appearance of a low-dose CT examination.
Low-dose CT lends itself well to thoracic imaging, partly
due to the high inherent tissue contrast in the lungs. Low-
dose CT in the abdomen and pelvis is challenging due to sim-
ilar densities of adjacent structures and little difference
between the attenuations of normal and pathological pro-
cesses that can be easily obscured by increased image noise
in the low-dose setting. For example, the identification of
subtle stranding of the fat or prominence of the vasa recta
associated with inflamed loops of small bowel is sometimes
vital in the detection of active disease. Image noise in
low-dose CT images may potentially impact detection of
these subtleties.
New reconstructive algorithms, termed iterative recon-
struction, use a more complex process of image formation
from raw projectional data by taking into account the




Rotation time 0.5 s
Noise index 85 HU
Slice thickness 64× 0.625mm
Reconstruction width 3mm
ATCM= z-axis automated tube current modulation.
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scanner geometry and noise statistics and in some cases
mathematical models to incorporate the shape and nonlinear
polychromatic nature of the X-ray beam, the focal spot
geometry, and the three-dimensional shape of the voxels.
This more computationally intense method of image recon-
struction results in lower levels of image noise, and therefore,
the CT scans may be acquired using a reduced amount of
radiation while maintaining equivalent image quality. Hybrid
IR methods blend FBP with a percentage of iterative recon-
struction whereas pure model-based IR is a fully IR-based
image reconstruction algorithm. Many IR algorithms have
been shown to be reliable for image reconstruction in a
number of clinical settings including but not limited to cystic
fibrosis [68], urolithiasis [66], CT enterography [67], follow-
up of testicular cancer [69], and carotid angiography [70]
with most reporting dramatic dose reductions while main-
taining diagnostic image quality. In the setting of Crohn’s
disease, there have been several studies detailing markedly
reduced radiation exposure from CT due to the utilization
of iterative reconstruction algorithms [55, 71–74], with dose
reductions reported from 34 to 74% compared with standard
dose CT-AP. This represents an effective dose reduction
from 3.5mSv to 0.98mSv with no significant differences in
terms of diagnostic ability reported (Figures 1–3).
Iterative reconstruction methods for low-dose CT rely on
the modelling of statistical characteristics in the image
domain. The current methods for this direct processing of
reconstructed images lead to significant amounts of image
noise. Innovative application of deep learning technology
has demonstrated a great potential of deep learning for noise
suppression, structural preservation, and lesion detection
at a high computational speed for low-dose CT imaging
[75]. This development of a specialized neural network
may lend itself to future applications such as 3D and
dynamic reconstruction as well as adaptation to other
imaging modalities.
A recent retrospective study comparing a novel IR algo-
rithm improved sinogram-affirmed iterative reconstruction
(SAFIRE∗, Siemens Healthcare, Erlangen, Germany), with
the standard filtered back projection (FBP). It was found that
half-dose CT datasets reconstructed with SAFIRE∗ main-
tained acceptable image quality compared with full-dose
CT datasets reconstructed with FBP [76]. The IR algorithm
in this case, though a research-only prototype currently,
potentially allows dose reductions in the order of 50% over
conventional CT scans.
While preliminary low-dose protocol optimization can
be performed with anthropomorphic and quality insurance
phantoms, individual patient size characteristics, such as
body weight, body-mass-index, and effective diameter, can
readily change the performance of some dose-reduction
tools. As iterative reconstruction algorithms are nonlinear,
results from phantom measurements will not predict perfor-
mance in humans. Also, the alteration of low-dose protocol
parameters is not usually feasible during routine clinical
practice because adequate diagnostic image quality must be
ensured for all CT studies. This problem has led to the devel-
opment of simulation tools that subsequently simulate low-
dose data from clinically acquired high-dose scans allowing
clinicians to improve low-dose protocols using patient data
acquired during clinical practice [77].
This tool has been used to determine the lowest achiev-
able radiation dose using iterative reconstruction for CT
imaging of the appendix in young adults [78]. A 1.0mSv
appendiceal CT was found to be noninferior to 2.0mSv CT
in terms of diagnostic performance. These results point to
the possibilities that simulation tools offer to clinical
departments.
The projection data from previously acquired patient
scans enable researchers to optimize the performance of iter-
ative reconstruction algorithms. With standardized data sets,
researchers from any discipline could evaluate IR algorithms
(a) (b)
Figure 1: (a) Conventional dose CT reconstructed with ASIR and (b) low-dose CT reconstructed with MBIR demonstrating terminal ileum
mural thickening and prominent vasa recta suggestive of acute inflammation. The low-dose CT entails an approximately 75% radiation dose
reduction (reduced from 3.5mSv to 0.98mSv).
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against the results of competing methods, helping them to
more rapidly determine which methods optimally reduce
radiation dose [79].
With the number of CT study acquisitions increasing
annually, it is paramount to further develop innovative dose
reduction tools while expanding the utility of abdominal
CT diagnostics.
Another important aspect of low-dose CT acquisitions
is patient positioning. A recent study investigated the
effect of patient off-centering in human cadavers [80].
Failure to ensure correct patient positioning resulted in a
dose overestimation of up to 92%. Techniques such as
laser-guided automatic patient-centering software have
the potential to offer dose saving of up to 30% for chest
CT and up to 56% for abdominal CT [81]. This empha-
sizes the valuable function such techniques have in CT
organ dose conservation.
4. Conclusion
Patients with Crohn’s disease are susceptible to high cumula-
tive radiation exposures, particularly patients with recurrent
disease and those who require steroid administration or
surgery. In order to minimise radiation exposure to patients
with Crohn’s disease, imaging methods which do not entail
ionizing radiation need to be used where possible. Neverthe-
less, there is a continuous global trend towards increased use
of CT in medical imaging which is particularly relevant for
patients with Crohn’s disease who are frequently young at
diagnosis and require lifelong imaging [56]. Recent develop-
ments in CT technology have the potential to considerably
reduce the ionizing radiation exposure to patients with CD.
Concerns remain regarding the risk of patient exposure to
ionizing radiation, and with CT contributing most to medical
radiation dose, it is imperative that we continue to strive for
continuous improvements in patient radiation protection in
order to keep radiation exposure as low as reasonably achiev-
able. Many recent research studies have focused on the utility
of new iterative image reconstruction algorithms in this
regard and have highlighted the ability of these new software
developments to facilitate the CT scanning at low-doses
while maintaining diagnostic image quality. Future research
will focus on optimizing these algorithms even further in
order to achieve the minimum CT radiation dose without
compromising diagnostic ability. There is little doubt that
CT will retain a central role in imaging of Crohn’s disease
(a) (b)
(c) (d)
Figure 2: (a, c) Conventional dose axial and coronal CT reconstructed with ASIR and (b, d) low-dose axial and coronal CT reconstructed with
MBIR demonstrating mural thickening at the terminal ileum and adjacent mild fat stranding consistent with acute inflammation. The
low-dose CT entails an approximately 75% radiation dose reduction.
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patients, but optimization of radiation exposure must remain
central to future developments.
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